US Pharma MarketingEisai and CORE Biomedicine agree on global licence for oncology pipeline
Eisai and CORE Biomedicine agree on global licence for oncology pipeline is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes.
Source: Pharmaceutical Technology